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The incidence of colorectal cancer (CRC) 
is rapidly increasing world-wide including in 
Indonesia and controversy not with standing, 
making it as the second most common malignancy 
(GLOBOCAN 2012). As with other cancers – 
more importantly with its adenoma-carcinoma 
sequence being one of the first to be elucidated 
by Vogelstein1 – its treatment and prognosis are 
determined by disease staging and molecular 
profile. Yet, identifying those for whom 
chemotherapy is indicated is still a challenge 
due to its histopathological heterogeneity; with 
special emphasis on stage II disease, for example, 
having a five-year survival that ranges from 
87.5% for IIA to 58.4% in stage IIC. It is in such 
situation that predictive and prognostic markers 
are constantly being investigated.
As one of the leading causes of cancer 
death in developed countries, much interest 
has grown in research in the development of 
biomarkers to improve the diagnostic process 
and to predict efficacy of chemotherapy.2 Only 
a few biomarkers are qualified as such, and 
the paucity of data has resulted in under- and 
overtreatment when relying only on the current 
TNM system. At present, only mutant KRAS, 
mutant BRAF, Microsatellite Instability (MSI) 
and the Oncotype DX® ColonCancer Assay are 
used in clinical practice. MSI and mutant KRAS 
are the established markers to date.3 But as the 
world is shifting towards personalized medicine 
(or “precision therapy” as is more frequently 
called), much work remains to be done.
Which brings us to the topic of BRAF in this 
edition of Acta Medica Indonesiana. Identified 
in several cancers such as melanoma, thyroid 
cancer, glioma, lung cancer, sarcoma, breast and 
colorectal aner, it is part of the Ras-Raf-MEK-
ERK pathway, having important functions in cell 
division, differentiation, migration, apoptosis 
and protein secretion.4
The V600E mutation is found in 80% of 
all BRAF mutations in the abovementioned 
cancers, with enhanced kinase activities for 
B-Raf resulting in constitutive activation of 
the downstream signaling pathway, leading to 
increased cell proliferation and survival.
Current research reveals that 9-14% of 
colorectal cancer patients have the BRAF V600E 
mutation, the mutation of which increased 
the risk of mortality two-fold. Combined 
with microsatellite instability assays, BRAF 
mutation showed that microsatellite stable and 
the BRAF mutation are independent adverse 
factors for patient survival, as the BRAF 
mutation in colorectal cancer rendered the tumor 
resistant to anti-EGFR therapy and wild-type 
BRAF is required for response to drugs such 
as panitumumab or cetuximab. Thus, BRAF 
genotype could be used to select eligible patients 
for the treatment with these drugs.
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However, although testing for K-ras mutations 
is recommended in metastatic colorectal cancer 
to determine whether an anti-EDFR drug such 
as cetuximab, should be used only if the tumor is 
negative for KRAS (wild-type); yet 30-40% will 
not respond. Thus, additional biomarkers will 
have to be used, and the BRAF V600E mutation 
is one of these markers for which early evidence 
showed improvement in the stratification of K-ras 
negative mCRC patients,5 and acknowledging 
the ethnic and populations among countries – 
thus the paper reporting among Indonesians –, 
the work of Hernowo is in the right direction, 
and future research is anticipated to elucidate 
the behavior of this cancer among Indonesians.
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